An update on the pharmacological management of autoimmune hepatitis. (24th July 2021)

• Record Type: Journal Article
• Authors: Chung, Yooyun; Rahim, Mussarat N; Graham, Jonathon J; Zen, Yoh; Heneghan, Michael A
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 11(2021)
• Page Start: 1475
• Page End: 1488
• Publication Date: 2021-07-24
• Subjects: Autoimmune hepatitis -- immunosuppression -- overlap syndrome -- pregnancy -- drug induced liver injury -- autoimmune pancreatitis -- Tregs; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2021.1895747
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Autoimmune hepatitis (AIH) is an immune mediated, inflammatory disease affecting the liver as a result of environmental triggers in susceptible individuals leading to loss of self-tolerance. The immunopathogenesis of AIH is not fully understood, which limits targeted therapeutic options. Areas covered : In this review, the authors provide an overview of current practice in the management of AIH, which include induction therapy with corticosteroids (± thiopurines), followed by maintenance therapy. Lack of early response to treatment may serve as a predictor of those at risk of requiring treatment escalation to second- and third-line agents such as mycophenolate mofetil (MMF), calcineurin inhibitors or biologics. Evidence for third-line agents from small retrospective studies or individual centers are reviewed. The nuances of AIH treatment in pregnancy, overlap syndromes, and drug induced liver injury (DILI) warrant further consideration. Expert opinion : Augmenting the balance of regulatory T cells (Treg) and effector T cells is an appealing therapeutic target with a multitude of agents in development. Many of the challenges in AIH research are due to its rarity and lack of randomized data. Management of AIH should strive towards individualized care through risk stratification and use of the best therapeutic modality for each patient.